Navigation Links
HemoSonics Appoints Timothy Fischer President and Chief Executive Officer
Date:8/5/2014

CHARLOTTESVILLE, Va., Aug. 5, 2014 /PRNewswire/ -- HemoSonics, a medical diagnostic company developing a novel point-of-care instrument to measure coagulation, announced today that it has named Timothy J. Fischer as President and Chief Executive Officer. Fischer has been a pioneer in the in vitro diagnostics industry in the fields of hematology, oncology and pathology for the past 25 years. He has led the design, development and commercialization of dozens of novel diagnostic products. He holds over 40 patents and has authored numerous publications.

"We are pleased and fortunate to have Tim leading our Company as we turn the corner to commercialization," said William Moffitt, Chairman of the Board of Managers for HemoSonics. "His extensive knowledge of hemostasis and his experience in building high performing product development teams will enable us to fulfill our vision of delivering critical patient information at the point of care."

Prior to joining HemoSonics, Fischer served as Chief Operating Officer for LipoScience, a publicly traded in vitro diagnostics company. At LipoScience, he led the successful development of the Vantera® Clinical Analyzer from concept through development, regulatory approval and market adoption. Before joining LipoScience, he served as Vice President of Development for the Women's Health and Cancer business unit at Becton Dickinson (BD) and as the Vice President of Product Development for TriPath Oncology.

"HemoSonics' novel technology enables an unparalleled product that will save lives and reduce healthcare costs by providing comprehensive information in an easy to use format," said Fischer. "I am thrilled to be part of a team that will revolutionize hemostasis testing and directly impact patient care in the critical care setting."

Fischer holds a Bachelor of Science degree in Biology from Indiana University.

About HemoSonics, LLC

HemoSonics, LLC (http://hemosonics.com), an in vitro diagnostics company, is developing and commercializing a novel ultrasound technology to address a significant unmet need in critical patient care.  Bleeding and clotting disorders are a major cause of morbidity and mortality, leading to complications, worse outcomes and longer hospital stays. HemoSonics is developing a platform and assays to identify coagulation dysfunctions in whole blood at the point-of-care in acute care settings, enabling physicians to improve quality of care while reducing overall healthcare costs.

HemoSonics' technology and products are currently labeled as Research Use Only and are not intended for clinical use at this time.

HemoSonics Contact:
Megan Shaw
(434) 260-0682
mshaw@hemosonics.com


'/>"/>
SOURCE HemoSonics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. TB Alliance Appoints Willo Brock Senior Vice President, External Affairs
2. invendo medical Appoints Nachum (Homi) Shamir To The Companys Board Of Directors
3. Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President
4. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
5. ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development
6. Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
7. Pharmavite Appoints Timothy Toll Chief Customer Officer
8. Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer
9. BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors
10. PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board
11. Nonin Medical Appoints Ash Keswani Vice President of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 2017 West Pharmaceutical Services, Inc. ... injectable drug administration, today announced that it will release ... Thursday, October 26, 2017, and will follow with a ... at 9:00 a.m. Eastern Time. To participate on the ... conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):